🇺🇸 FDA
Pipeline program

Tecentriq 840 mg concentrate for solution for infusion

MO43156

Phase 2 small_molecule active

Quick answer

Tecentriq 840 mg concentrate for solution for infusion for Non-Small Cell Lung Cancer (NSCLC) is a Phase 2 program (small_molecule) at Roche Registration Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Roche Registration Limited
Indication
Non-Small Cell Lung Cancer (NSCLC)
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials